Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rethinking Alzheimer's: Mapping Out an Approval Process

This article was originally published in RPM Report

Executive Summary

Drug companies involved in Alzheimer's disease research are a little fed up with FDA. Some, like Wyeth, believe the agency should put Alzheimer's research higher up on its priority list and allow the use of surrogate endpoints for clinical trials. But FDA says that no validated surrogate exists for Alzheimer's, and until it has hard data from products in development, it is loath to recommend one. A recent reorganization of the agency's neurology group may provide an opening to press home those arguments.
Advertisement

Related Content

Alzheimer’s Imaging Agents Should Be Validated With Autopsies, Panel Says
Pfizer Goes Deeper Into Alzheimer’s Market With Medivation Deal
Wyeth Halts Alzheimer’s Vaccine Trial, Drops HCV Candidate
Prana: New Cognition Test Works In Alzheimer’s Trial
Trailblazing Alzheimer’s Drugs Move Into Late-Stage Development
Straight Talk from FDA: Wyeth R&D Head Reacts to Climate Change for NDA/BLA Reviews
Clinical Update (10/2007)
Alzheimer’s imaging pact
Elan/Wyeth Move Novel Alzheimer’s Treatment Into Phase III
Deals Shaping the Medical Industry (5/07)

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS080024

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel